Sun Pharma reports strong FY25, appoints new leadership, expands pipeline
** Sun Pharmaceutical Industries reported strong financial results for FY25, driven by growth in key segments and strategic advancements. The company's global consolidated revenues grew by 9.0% to INR 520 Billion, while EBITDA increased by 17.3% to INR 153 Billion, and adjusted net profit rose by 19.0% to INR 120 Billion. The Global Specialty business continues to be a growth driver, contributing 20% to consolidated revenue, up from 18% in FY24. Sun Pharma is also increasing its focus on Environmental, Social and Governance (ESG) principles throughout all operations and has been included in the S&P Global Sustainability Yearbook 2025 as recognition of these ongoing efforts.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
News Alerts
Get instant email alerts when Sun Pharmaceutical Industries publishes news
Free account required • Unsubscribe anytime